Curaleaf Holdings, Inc. (OTCMKTS:CURLF) Given Average Rating of “Buy” by Analysts

Shares of Curaleaf Holdings, Inc. (OTCMKTS:CURLF) have been assigned an average recommendation of “Buy” from the five research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, two have assigned a buy recommendation and two have assigned a strong buy recommendation to the company.

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group upgraded shares of Curaleaf to a “strong-buy” rating in a research report on Thursday, October 9th. Atb Cap Markets upgraded Curaleaf from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 2nd. Alliance Global Partners reissued a “buy” rating on shares of Curaleaf in a report on Monday, December 22nd. ATB Capital raised shares of Curaleaf to an “outperform” rating in a report on Tuesday, December 2nd. Finally, Zacks Research upgraded Curaleaf from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st.

Curaleaf Stock Performance

Shares of CURLF stock opened at $2.21 on Wednesday. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.47 and a quick ratio of 0.71. The company has a market cap of $1.50 billion, a P/E ratio of -6.91 and a beta of 0.73. Curaleaf has a one year low of $0.68 and a one year high of $5.05. The firm has a 50-day moving average of $2.69 and a 200-day moving average of $2.57.

Curaleaf (OTCMKTS:CURLF) last announced its earnings results on Wednesday, November 5th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Curaleaf had a negative return on equity of 15.57% and a negative net margin of 19.50%. Equities research analysts forecast that Curaleaf will post -0.25 EPS for the current fiscal year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.